Background—In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the angiotensin-converting enzyme inhibitor enalapril in patients with heart failure and reduced ejection fraction. We examined whether this benefit was consistent irrespective of background therapy. Methods and Results—We examined the effect of study treatment in the following subgroups: diuretics (yes/no), digitalis glycoside (yes/no), mineralocorticoid receptor antagonist (yes/no), and defibrillating device (implanted defibrillating device, yes/no). We also examined the effect of study drug accord...
Background—The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardi...
Background Compared to heart failure patients with higher systolic blood pressure (SBP), those with ...
Importance The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a...
Objectives: This study assessed whether the benefit of sacubtril/valsartan therapy varied with c...
AbstractObjectivesThis study assessed whether the benefit of sacubtril/valsartan therapy varied with...
Background: Compared to heart failure patients with higher systolic blood pressure (SBP), those w...
The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular m...
Background: Angiotensin converting enzyme inhibitors (ACE-I), are beneficial both in heart failu...
Background: Angiotensin converting enzyme inhibitors (ACE-I), are beneficial both in heart failu...
Objectives The purpose of this study was to compare outcomes (and the effect of sacubitril/valsartan...
Aims Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but c...
In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mor...
Purpose: To systematically assess the efficacy and safety of sacubitril/valsartan (SV) by comparison...
Aims: Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but ...
Aims: In this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants...
Background—The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardi...
Background Compared to heart failure patients with higher systolic blood pressure (SBP), those with ...
Importance The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a...
Objectives: This study assessed whether the benefit of sacubtril/valsartan therapy varied with c...
AbstractObjectivesThis study assessed whether the benefit of sacubtril/valsartan therapy varied with...
Background: Compared to heart failure patients with higher systolic blood pressure (SBP), those w...
The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular m...
Background: Angiotensin converting enzyme inhibitors (ACE-I), are beneficial both in heart failu...
Background: Angiotensin converting enzyme inhibitors (ACE-I), are beneficial both in heart failu...
Objectives The purpose of this study was to compare outcomes (and the effect of sacubitril/valsartan...
Aims Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but c...
In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mor...
Purpose: To systematically assess the efficacy and safety of sacubitril/valsartan (SV) by comparison...
Aims: Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but ...
Aims: In this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants...
Background—The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardi...
Background Compared to heart failure patients with higher systolic blood pressure (SBP), those with ...
Importance The angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a...